BridgeMD
New treatment option for Acute Coronary Syndromes (ACS)
Official title Influenza Vaccination After Acute Coronary Syndrome
ClinicalTrials.gov ID: NCT07259252
What this study is testing
What is Influenza vaccine?
Influenza vaccine is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for acute coronary syndromes (acs).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to learn if influenza vaccination can prevent adverse cardiac events in Chinese acute coronary syndrome patients. The main questions it aims to answer are: Whether influenza vaccination can decrease events of cardiovascular death, MI, or stroke?
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- ACS patient aged from 18 to 80 years.
- Volunteer for the study and written informed consent.
You likely can't join if
- Participate in any drug clinical trials within 3 months.
- Patients with life-threatening complications, or the researchers determined that the survival time of patients with no more than 1 years.
- Serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients).
- Previous history of cancer or tumor, or pathological examination confirmed precancerous lesions (such as breast ductal carcinoma in situ, or atypical...
- Patients refused to comply with the requirements of this study to complete the research work.
- Patients Received influenza vaccination within 1 year.
See the full eligibility criteria
- ACS patient aged from 18 to 80 years.
- Volunteer for the study and written informed consent.
- Participate in any drug clinical trials within 3 months.
- Patients with life-threatening complications, or the researchers determined that the survival time of patients with no more than 1 years.
- Serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients).
- Previous history of cancer or tumor, or pathological examination confirmed precancerous lesions (such as breast ductal carcinoma in situ, or atypical hyperplasia of the cervix).
- Patients refused to comply with the requirements of this study to complete the research work.
- Patients Received influenza vaccination within 1 year.
- Patients with contraindications for influenza vaccination.
The study team makes the final eligibility decision.
Where it's taking place
- Wuhan, Hubei, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Wuhan, Hubei, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.